Benazepril slows progression of renal dysfunction in patients with non-diabetic renal disease

Nephrology

Volumn 12, Issue 3, 2007, Pages 294-298

  Ishimitsu, Toshihiko ^a   Akashiba, Akira ^a   Kameda, Tomoko ^a   Takahashi, Toshiaki ^a   Ohta, Satoshi ^a   Yoshii, Masayoshi ^a   Minami, Junichi ^a   Ono, Hidehiko ^a   Numabe, Atsushi ^a   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Benazepril; Non diabetic renal disease; Proteinuria; Renal dysfunction

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMIDAPRIL; MANIDIPINE; NIFEDIPINE; PLACEBO; POTASSIUM; PROTEIN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DISEASE COURSE; DRUG DOSE INCREASE; DRUG SUBSTITUTION; FEMALE; HUMAN; KIDNEY FAILURE; LONG TERM CARE; MALE; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; URINALYSIS;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZAZEPINES; BLOOD PRESSURE; CREATINE; CROSS-OVER STUDIES; FEMALE; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; PROTEINURIA; RENAL INSUFFICIENCY;

EID: 34248216956     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2007.00786.x     Document Type: Article

References (36)

1. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am. J. Physiol. 1981 241 : F85 F93.
2. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: A paradigm shift in nephrology. Kidney Int. 1996 49 : 1774 7.
3. Romero JC, Ruilope LM, Bentley MD, Fiksen-Olsen MJ, Lahera V, Vidal MJ. Comparison of the effects of calcium antagonists and converting enzyme inhibitors on renal function under normal and hypertensive conditions. Am. J. Cardiol. 1988 62 : 59G 68G.
4. Carmines PK, Mitchell KD, Navar LG. Effects of calcium antagonists on renal hemodynamics and glomerular function. Kidney Int. Suppl. 1992 36 : S43 S48.
5. Raij L. Recommendations for the management of special populations: Renal disease in diabetes. Am. J. Hypertens 2003 16 : 46S 49S.
6. Parving HH, Andersen S, Jacobsen P et al. Angiotensin receptor blockers in diabetic nephropathy: Renal and cardiovascular end points. Semin. Nephrol. 2004 24 : 147 57.
7. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996 334 : 939 45.
8. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997 349 : 1857 63.
9. African American Study of Kidney Disease and Hypertension Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 2001 285 : 2719 28.
10. Hou FF, Zhang X, Zhang GH et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. 2006 354 : 131 40.
11. Lakkis J, Weir MR. Pharmacological strategies for kidney function preservation: Are there differences by ethnicity? Adv. Ren. Replace. Ther. 2004 11 : 24 40.
12. Adler S. Renal disease: Environment, race, or genes? Ethn. Dis. 2006 16 (Suppl. 2 S35 S39.
13. The Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The sixth report of the Joint National Committee on prevention, detection evaluation and treatment of high blood pressure. Arch. Intern. Med. 1997 157 : 2413 46.
14. Wolf G. Angiotensin II as a mediator of tubulointerstitial injury. Nephrol. Dial. Transplant. 2000 15 (Suppl. 6 61 3.
15. Luft FC. Proinflammatory effects of angiotensin II and endothelin: Targets for progression of cardiovascular and renal diseases. Curr. Opin. Nephrol. Hypertens. 2002 11 : 59 66.
16. Juknevicius I, Segal Y, Kren S, Lee R, Hostetter TH. Effect of aldosterone on renal transforming growth factor-beta. Am. J. Physiol. Renal Physiol. 2004 286 : F1059 F1062.
17. Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. J. Am. Soc. Nephrol. 2003 14 : 2395 401.
18. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: Effects on kidney disease. Am. J. Med. 2004 116 : 263 72.
19. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 1993 329 : 1456 62.
20. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000 355 : 253 9.
21. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001 345 : 861 9.
22. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001 345 : 851 60.
23. Ishimitsu T, Kameda T, Akashiba A et al. Effects of valsartan on the progression of chronic renal insufficiency in patients with non-diabetic renal disease. Hypertens. Res. 2005 28 : 865 70.
24. Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 2005 366 : 2026 33.
25. Ruggenenti P. Angiotensin-converting enzyme inhibition and angiotensin II antagonism in non-diabetic chronic nephropathies. Semin. Nephrol. 2004 24 : 158 67.
26. Iino Y, Hayashi M, Kawamura T et al. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension - A report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens. Res. 2004 27 : 21 30.
27. Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann. Intern. Med. 1995 123 : 754 62.
28. Remuzzi G, Chiurchiu C, Ruggenenti P. Proteinuria predicting outcome in renal disease: Non-diabetic nephropathies (REIN). Kidney Int. Suppl. 2004 92 : S90 S96.
29. Abbate M, Benigni A, Bertani T, Remuzzi G. Nephrotoxicity of increased glomerular protein traffic. Nephrol. Dial. Transplant. 1999 14 : 304 12.
30. Abbate M, Zoja C, Morigi M et al. Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: A central pathway in progressive glomerulosclerosis. Am. J. Pathol. 2002 161 : 2179 93.
31. Kannel WB, Stampfer MJ, Castelli WP, Verter J. The prognostic significance of proteinuria: The Framingham study. Am. Heart J. 1984 108 : 1347 52.
32. Culleton BF, Larson MG, Parfrey PS, Kannel WB, Levy D. Proteinuria as a risk factor for cardiovascular disease and mortality in older people: A prospective study. Am. J. Med. 2000 109 : 1 8.
33. Dykeman-Sharpe J. Proteinuria, a modifiable risk factor: Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). CANNT J. 2003 13 : 34 8.
34. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003 289 : 2560 72.
35. European Society of Hypertension - European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 2003 21 : 1011 153.
36. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 2003 361 : 117 24.